Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers.
Large intragenic deletions of the TSG101/CC2 gene were recently reported in seven of 15 primary metastatic breast cancers. Although the number of samples was small, this observation suggested that TSG101/CC2 alterations were a major event in breast carcinogenesis. To study the frequency of these deletions in invasive breast cancers we analysed 189 primary invasive breast tumours and 59 breast cancer metastases. We detected intragenic rearrangements in only three samples (two primary tumours and one metastasis). Northern blot analysis of 43 tumours without rearrangements failed to detect any abnormalities. Furthermore, we studied TSG101/CC2 in 11 human breast adenocarcinoma cell lines by Southern blot, RT-PCR and sequencing of the entire coding region of the gene, and detected no abnormalities. These results show that genetic alteration of TSG101/CC2 is a rare event in breast cancer.
Wang
Q
Q
Unité d'Oncologie Moléculaire, Unité INSERM U453, Centre Léon Bérard, Lyon, France.
Driouch
K
K
Courtois
S
S
Champème
M H
MH
Bièche
I
I
Treilleux
I
I
Briffod
M
M
Rimokh
R
R
Magaud
J P
JP
Curmi
P
P
Lidereau
R
R
Puisieux
A
A
D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology*; D000483:Alleles; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D005260:Female; D017353:Gene Deletion; D006801:Humans; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D016133:Polymerase Chain Reaction; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm